DLL4
Delta-like protein 4
As of the edition of 20 October 2026, DLL4 (delta-like protein 4, UniProt Q9NR61) has 4 drugs tested at it and 4 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NR61
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Cancer; Digestive system; Hormones; Pregnancy and women's health; Urinary and reproductive; Lungs and airways; Skin and connective tissue
- Registered trials of its drugs
- 15
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Demcizumab | Went quiet | Phase 2 | none listed |
| Navicixizumab | Active | Phase 3 | none listed |
| Dilpacimab | Stopped | Phase 2 | none listed |
| Enoticumab | Went quiet | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 1 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| AbbVie | Route A |
| Regeneron | Route A |
| Mereo BioPharma | Route A |
The other 1 company at DLL4
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at DLL4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.